Drugmaker says it expects to transition to ‘modest profitability’ as it receives new orders
AstraZeneca has started signing commercial contracts to supply its Covid-19 vaccine next year as the pandemic moves to an “endemic phase” – in a major shift away from the drugmaker’s not-for-profit pricing.
Britain’s biggest pharma firm expects the vaccine to move to “modest profitability” as new orders are received. However, the chief executive, Pascal Soriot, insisted that it was offering affordable and tiered pricing, depending on countries’ ability to pay. He said the vaccine, developed with Oxford University, would not become “a huge profit earner”.
Read the original article at The Guardian